↓ Skip to main content

Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults

Overview of attention for article published in BMC Cancer, October 2009
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
121 Dimensions

Readers on

mendeley
107 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
Published in
BMC Cancer, October 2009
DOI 10.1186/1471-2407-9-372
Pubmed ID
Authors

Pierre A Robe, Didier H Martin, Minh T Nguyen-Khac, Maria Artesi, Manuel Deprez, Adelin Albert, Sophie Vanbelle, Stephane Califice, Markus Bredel, Vincent Bours

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 <1%
Belgium 1 <1%
Brazil 1 <1%
Unknown 104 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 16%
Student > Ph. D. Student 16 15%
Student > Master 15 14%
Student > Bachelor 12 11%
Student > Doctoral Student 5 5%
Other 18 17%
Unknown 24 22%
Readers by discipline Count As %
Medicine and Dentistry 27 25%
Biochemistry, Genetics and Molecular Biology 15 14%
Agricultural and Biological Sciences 13 12%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Neuroscience 5 5%
Other 11 10%
Unknown 30 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2017.
All research outputs
#2,796,614
of 10,393,133 outputs
Outputs from BMC Cancer
#848
of 4,112 outputs
Outputs of similar age
#76,332
of 221,443 outputs
Outputs of similar age from BMC Cancer
#20
of 98 outputs
Altmetric has tracked 10,393,133 research outputs across all sources so far. This one has received more attention than most of these and is in the 54th percentile.
So far Altmetric has tracked 4,112 research outputs from this source. They receive a mean Attention Score of 3.9. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 221,443 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.